新桥生物(NBP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBP 新桥生物

盘前交易 09-14 04:23:43 EDT

1.59

-0.10

-5.92%

最高1.71	最低1.58	成交量25.28万
今开1.70	昨收1.69	日振幅7.69%
总市值1.84亿	流通市值1.03亿	总股本1.16亿
成交额40.72万	换手率0.39%	流通股本6,456万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新桥生物","latestPrice":1.59,"timestamp":1789156800000,"preClose":1.69,"halted":0,"volume":252833,"delay":0,"changeRate":-0.059171597633136015,"floatShares":64563600,"shares":115999216,"eps":-0.6591,"marketStatus":"盘前交易","change":-0.1,"latestTime":"09-14 04:23:43 EDT","open":1.7,"high":1.71,"low":1.58,"amount":407188.6083986,"amplitude":0.076923,"askPrice":1.72,"askSize":100,"bidPrice":1.46,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.6591,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.59,"postHourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.59,"latestTime":"19:51 EDT","volume":216,"amount":349.42,"timestamp":1789170664750,"change":0.03,"changeRate":0.018868,"amplitude":0.018868},"volumeRatio":1.575022456061781,"impliedVol":0.9503,"impliedVolPercentile":0.447},"requestUrl":"/m/hq/s/NBP","defaultTab":"news","newsList":[{"id":"1165817918","title":"新桥生物发布2026年上半年财务业绩，彰显管线动能与战略执行力","url":"https://stock-news.laohu8.com/highlight/detail?id=1165817918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165817918?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:01","pubTimestamp":1787223693,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）今日披露了截至2026年6月30日的上半年财务报告，同时对外强调了其研发管线的持续推进态势，以及公司在战略层面所展现出的高效执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110507548","title":"新桥生物将于2026年8月20日（周四）披露2026年上半年财务业绩并发布公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1110507548","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110507548?lang=zh_cn&edition=full","pubTime":"2026-08-14 05:01","pubTimestamp":1786654869,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）计划于2026年8月20日（星期四）公布其2026年上半年财务报告，届时也将同步更新公司业务进展与战略部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199400680","title":"新桥生物旗下Givastomig的注册性三期临床试验最早有望于2026年第四季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1199400680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199400680?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:01","pubTimestamp":1781607678,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，其核心候选药物Givastomig的注册性三期临床试验，预计最早将于2026年第四季度开始。这一关键性试验的启动，标志着该药物在特定适应症研发进程中迈入决定性阶段，为后续的监管申报和潜在商业化铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148595922","title":"新桥生物Givastomig获FDA快速通道资格，用于一线治疗HER2阴性转移性胃癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1148595922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148595922?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:00","pubTimestamp":1781607647,"startTime":"0","endTime":"0","summary":"新桥生物宣布，其研发的Givastomig已获得美国食品药品监督管理局（FDA）授予的快速通道资格，该资格针对的适应症为一线治疗HER2阴性转移性胃癌。此项认定有望加速该药物的研发与审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120501405","title":"新桥生物：FDA确认Givastomig有望符合加速审批资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1120501405","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120501405?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:39","pubTimestamp":1773664740,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式确认，新桥生物（NovaBridge Biosciences）旗下在研药物Givastomig具备潜在资格，有望通过加速审批通道推进上市进程。\n这一进展意味着，若后续临床试验数据积极，Givastomig或可基于替代终点提前获批，从而缩短其进入市场的时间。加速审批路径通常适用于针对严重疾病、且现有治疗选择有限的创新疗法。\n新桥生物表示，将继续与FDA保持密切沟通，积极推进Givastomig的临床开发计划，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139570168","title":"新桥生物计划于2026年第四季度启动以客观缓解率为主要终点的注册性三期联合试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1139570168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139570168?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:03","pubTimestamp":1773658990,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，公司将于2026年第四季度正式启动一项注册性三期联合疗法临床试验。该试验将采用客观缓解率（ORR）作为主要疗效终点，旨在评估创新疗法组合在目标患者群体中的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106527073","title":"新桥生物宣布与FDA就胃腺癌药物Givastomig加速审批路径达成建设性B类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1106527073","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106527073?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:02","pubTimestamp":1773658924,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）近日披露，该公司与美国食品药品监督管理局（FDA）针对其在研药物Givastomig用于治疗胃腺癌的加速批准路径，成功举行了一场富有成效的B类会议。\n此次会议重点探讨了Givastomig通过加速审批通道上市的可能性，双方就后续临床开发策略及数据要求达成重要共识。该进展标志着Givastomig在胃腺癌治疗领域的商业化进程迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novabridge.com","stockEarnings":[{"period":"1week","weight":-0.1167},{"period":"1month","weight":-0.1497},{"period":"3month","weight":0.0671},{"period":"6month","weight":-0.4382},{"period":"1year","weight":-0.5923},{"period":"ytd","weight":-0.6005}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"新桥生物于2016年6月30日在开曼群岛注册成立。该公司是一家全球生物技术平台，专注于开发创新的免疫肿瘤疗法。其研发管线包括三个临床阶段项目，其中givastomig是一种用于治疗胃癌的CLDN18.2双特异性抗体，是公司的核心产品。通过其子公司Visara，公司还在开发用于视网膜疾病的VIS-101。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.014966},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.04486},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.139701},{"month":4,"riseRate":0.571429,"avgChangeRate":0.057761},{"month":5,"riseRate":0.571429,"avgChangeRate":0.069758},{"month":6,"riseRate":0.857143,"avgChangeRate":0.201798},{"month":7,"riseRate":0.142857,"avgChangeRate":-0.089766},{"month":8,"riseRate":0.428571,"avgChangeRate":0.058211},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.079557},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.01521},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.055941},{"month":12,"riseRate":0.666667,"avgChangeRate":0.047406}],"exchange":"NASDAQ","name":"新桥生物","nameEN":"NovaBridge Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新桥生物(NBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新桥生物(NBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新桥生物,NBP,新桥生物股票,新桥生物股票老虎,新桥生物股票老虎国际,新桥生物行情,新桥生物股票行情,新桥生物股价,新桥生物股市,新桥生物股票价格,新桥生物股票交易,新桥生物股票购买,新桥生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新桥生物(NBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新桥生物(NBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}